Castleark Management LLC Grows Stock Holdings in Guardant Health, Inc. $GH

Castleark Management LLC increased its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 165,043 shares of the company’s stock after buying an additional 4,970 shares during the period. Castleark Management LLC owned about 0.13% of Guardant Health worth $16,857,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health in the 4th quarter worth about $27,000. Chesapeake Asset Management LLC purchased a new stake in shares of Guardant Health in the 4th quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health in the 4th quarter worth about $31,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health in the 4th quarter worth about $35,000. Finally, Parallel Advisors LLC boosted its position in shares of Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In related news, Director Meghan V. Joyce sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the transaction, the director owned 11,183 shares in the company, valued at approximately $1,420,017.34. This trade represents a 47.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer owned 2,012,919 shares in the company, valued at $254,231,669.70. The trade was a 4.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 452,238 shares of company stock valued at $51,425,612 over the last 90 days. 5.60% of the stock is currently owned by insiders.

Guardant Health Stock Up 0.6%

NASDAQ:GH opened at $131.62 on Friday. The company has a market cap of $17.45 billion, a P/E ratio of -38.83 and a beta of 1.61. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $134.28. The firm’s 50 day moving average is $103.51 and its two-hundred day moving average is $102.14.

Analyst Ratings Changes

Several equities research analysts recently commented on GH shares. Mizuho boosted their price objective on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday. Wells Fargo & Company boosted their price objective on shares of Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Leerink Partners boosted their price objective on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. Finally, The Goldman Sachs Group began coverage on Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.